Company intelligence / Profile preview
Radius Health Inc
Boston, Massachusetts, United States of Americaradiuspharm.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Lead product TYMLOS (abaloparatide) was approved by the FDA and launched in the U.S. in 2017 for treating postmenopausal women with osteoporosis at high risk for fracture. The company also offers Binosto, an effervescent tablet for treating osteoporosis.
- Therapeutic areas
- OncologyEndocrinologyRare DiseasesNeurology
- Modalities
- Small moleculesbiologics (abaloparatide injection)synthetic cannabidiol oral solution
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
TheramexTeijinLabatecPharmbio Korea IncBiosidusMenarini Group (for elacestrant)
Beyond the preview
Go deeper on Radius Health Inc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Radius Health Inc.